Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRADIENT: Relacorilant for Hypercortisolism Due to Cortisol-Secreting Adrenal Adenomas or Hyperplasia
2019-004956-12Phase 3Completed
- Sponsor
- Corcept Therapeutics
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cushing's syndrome, Adrenal adenoma, congenital adrenal hyperplasia (CAH) and 3 more comparing Relacorilant with Placebo (2 arms). Primary endpoint: Primary endpoint - Glycemic control. Started Jul 2020; status: completed.
02
Drugs
relacorilant
03
Conditions
Cushing's syndromeAdrenal adenomacongenital adrenal hyperplasia (CAH)hypertension (HTN)prediabetes
Beyond the preview
Go deeper on 2019-004956-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004956-12.